Clinical trials: Pneumococcal Vaccine
Pneumococcal Conjugate Vaccine
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
This study is to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal Conjugate Vaccine in children with Sickle Cell Disease who have already been vaccinated with 23-valent polysaccharide vaccine.
- Trial name
- NCT00918580
- Testing
- 13-valent Pneumoccocal Conjugate Vaccine
- Where
- 19 sites in United States, Egypt and 5 more
- Volunteers
- 158 people
- Sponsor
- Pfizer
Pneumococcal Infections
Early Versus Delayed Pneumococcal Vaccination in HIV
The purpose of this study is to determine whether people who are HIV-positive respond better to a vaccine for pneumonia-related disease when they are immunized immediately, or when immunization is delayed until the immune system…
- Trial name
- NCT00137605
- Testing
- Pneumovax, Prevnar
- Where
- 14 sites in Canada
- Volunteers
- 79 people
- Sponsor
- CIHR Canadian HIV Trials Network
Pneumococcal Polysaccharide Vaccine, Influenza Vaccines
Preoperative Pneumococcal and Influenza Vaccination to Prevent Postoperative Pulmonary Infection in Patients Undergoing Lung Resection for Pulmonary Nodules or Lung Cancer
Postoperative pneumonia (POP) affects 4%-24% of lung cancer surgery patients, increasing mortality, stay, costs and worsening prognosis, especially in older patients.
- Conditions
- Pneumococcal Polysaccharide Vaccine, Influenza Vaccines, Preoperative, Lung Resection Surgery
- Trial name
- NCT07885540
- Testing
- 23-valent pneumococcal polysaccharide vaccine, Quadrivalent split-virion influenza vaccine
- Volunteers
- 1,278 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Pneumococcal Diseases
A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60
This Phase I, randomized, double-blind, parallel-controlled study is to be conducted in healthy adults aged 60 and above. Participants will be randomly assigned in a 1:1 ratio to receive either 26-valent Pneumococcal Conjugate…
- Trial name
- NCT06970756
- Testing
- 26-valent Pneumococcal Conjugate Vaccine, 13-valent Pneumococcal Conjugate Vaccine
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Multiple Myeloma
Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM)
Multiple myeloma patients often get serious infections that can be deadly. A British study looked at newly diagnosed patients and found that bacterial infections were the main cause of death in the first 60 days, mostly from…
- Trial name
- NCT07154537
- Testing
- 2-dose PCV13, 1-dose PCV13
- Where
- Taiwan
- Volunteers
- 101 people
- Sponsor
- National Taiwan University Hospital
Aging
PPV: Pneumococcal Polysaccharide Vaccine in Older Adults
The purpose of this study is to measure how long the improvement in the immune system lasts in older people after they have been vaccinated, and to examine the immune response in older people who get vaccinated a second time.
- Trial name
- NCT00239694
- Testing
- Pneumococcal Vaccine, Meningococcal Vaccine
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Otitis Media
Effect of Prevnar 13 on Ear Infections in Children
Prevnar (7 valent pneumococcal conjugate vaccine [7vPnC]) has been shown to be effective against ear infections in children. Prevnar 13 is a new vaccine that is similar to Prevnar.
- Trial name
- NCT01199016
- Testing
- Tympanocentesis, Nose/throat swab, Observational
- Where
- 7 sites in United States
- Volunteers
- 239 people
- Sponsor
- Pfizer
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Adults Aged ≥18 Years
A Phase Ib/II clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24)developed by Sinovac Life Science Co., Ltd will be conducted in adults aged ≥18 years.
- Trial name
- NCT07543198
- Testing
- Sinovac Low-dosage PCV24, Sinovac Middle-dosage PCV24, Sinovac High-dosage PCV24
- Where
- China
- Volunteers
- 385 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Haemophilus Influenzae, Streptococcus Pneumoniae
Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK2231395A candidate vaccine in adults and elderly adults with chronic obstructive pulmonary disease.
- Trial name
- NCT00849069
- Testing
- GSK2231395A, TwinrixTM
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Immunogenicity, Vaccine, Immunologic Memory
Immunological Memory Against Pneumococcus Induced by 3 Infant PCV 13 Vaccination Schedules
The purpose of this study is to evaluate the establishment of immunological memory between the 3 different infant vaccination schedules with the 13-valent pneumococcal conjugate vaccine (PCV13) currently in use.
- Trial name
- NCT03405805
- Testing
- 13-valent pneumococcal conjugate vaccine (PCV13)
- Where
- Greece
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Aghia Sophia Children's Hospital of Athens
Vaccine Reaction
Safety and Immunogenicity of PCV-LITE, a Low-dose of Pneumococcal Conjugate Vaccine With LiteVax Adjuvant
Streptococcus pneumoniae is a common bacteria and major cause of serious infections like bloodstream infections, pneumonia, and meningitis.
- Trial name
- PCV-LITE (NCT06986239)
- Testing
- PCV-LITE, PCV-LITE+LVA, PCV20
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- LiteVax BV
Pneumococcal Infections
Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults
The 13-valent pneumococcal conjugate vaccine (13vPnC) is being developed for adults to prevent pneumococcal diseases such as meningitis (inflammation of the brain lining), septicemia (blood poisoning), and pneumonia (inflammation…
- Trial name
- NCT00492557
- Testing
- 13-valent pneumococcal conjugate vaccine, 13vPnC + TIV
- Volunteers
- 1,185 people, healthy volunteers welcome
- Sponsor
- Pfizer
Breast Neoplasm, Breast Cancer
Multipeptide Vaccine for Advanced Breast Cancer
This is a study on how to activate the immune system with a vaccine. The vaccine is made up of two proteins found in breast cancer: telomerase and survivin.
- Conditions
- Breast Neoplasm, Breast Cancer, Cancer of the Breast, Carcinoma, Ductal
- Trial name
- NCT00573495
- Testing
- hTERT/Survivin Multi-Peptide Vaccine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Pennsylvania
Infections, Streptococcal, Streptococcus Pneumoniae Vaccines
Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age
The purpose of this study is to assess the immunogenicity in terms of antibody response and the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse events following primary vaccination of…
- Trial name
- NCT00489554
- Testing
- Synflorix, Infanrix hexa, Rotarix
- Where
- 2 sites in Mexico
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Nasopharyngeal Carriage of Streptococcus Pneumoniae
Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage
The purpose of this study is to assess the direct effects of the ten-valent pneumococcal conjugate vaccine administered to infants on nasopharyngeal carriage at 3 to 5 years of age.
- Trial name
- NCT01925222
- Where
- Finland
- Volunteers
- 3,900 people, healthy volunteers welcome
- Sponsor
- Arto Palmu
Pneumococcal Infections
Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age
This Phase 1b will describe the safety and immunogenicity of 2 multivalent pneumococcal conjugate vaccine formulations in healthy Japanese adults in the United States.
- Trial name
- NCT03642847
- Testing
- Prevnar 13, multivalent pneumococcal conjugate formulation 1, multivalent pneumococcal conjugate formulation 2
- Where
- 4 sites in United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Vaccine Adverse Reaction
Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.
The purpose of this observational study is to examine the risk of adverse events following vaccination with 10 or 13-valent pneumococcal conjugate vaccine (PCV10 or PCV13) among infants or children age <59 months and 23-valent…
- Trial name
- NCT04551248
- Testing
- 10 or 13-valent pneumococcal conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine, Influenza vaccine
- Where
- South Korea
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Sungkyunkwan University
Pneumococcal Disease
A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults
The purpose of this clinical trial is to learn about a pneumococcal vaccine with a new ingredient (PF-07872411) intended to enhance the effects of the vaccine.
- Trial name
- NCT05831124
- Testing
- Low dose multivalent pneumococcal conjugate vaccine formulation A, Low dose multivalent pneumococcal conjugate vaccine formulation B, Low dose of multivalent pneumococcal conjugate vaccine control
- Where
- 9 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumonia, Meningitis
Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children
The study aims to evaluate the safety and immunogenicity of the 10-valent and 13-valent pneumococcal conjugate vaccines when administered in an accelerated schedule in Papua New Guinean children, who experience early dense upper…
- Conditions
- Pneumonia, Meningitis, Bacteraemia, Sepsis
- Trial name
- PCV1103 (NCT01619462)
- Testing
- Prevenar 13 and Synflorix
- Where
- Papua New Guinea
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Papua New Guinea Institute of Medical Research
Pneumococcal Infections
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
This study will assess the safety, tolerability and immune response of 13-valent pneumococcal conjugate vaccine (13vPnC) compared with 23-valent Pneumococcal Polysaccharide Vaccine (23vPS).
- Trial name
- NCT00427895
- Testing
- 13-valent pneumococcal conjugate vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
- Where
- 26 sites in United States
- Volunteers
- 2,141 people, healthy volunteers welcome
- Sponsor
- Pfizer